XL t(8;9) PCM1/JAK2 DF

Translocation/Dual Fusion Probe

Order Number
D-5120-100-OG
Package Size
100 µl (10 Tests)
Labels
  
Chromosomes
89
Regulatory Status
IVDD

IVDR Certification

This probe is IVDR-certified in compliance with the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR).

MetaSystems Probes has already certified a large part of its portfolio, according to IVDR. For organizational reasons, we currently provide only the IVDD product.

Please use the switch to change to the IVDR product.

IVDDIVDRDiscover all IVDR-certified products

Product Description

XL t(8;9) PCM1/JAK2 DF

XL t(8;9) PCM1/JAK2 DF consists of an orange-labeled probe hybridizing to the PCM1 gene region at 8p22 and a green-labeled probe hybridizing to the JAK2 gene region at 9p24.

Probe maps are created in accordance with the intended purpose of the product. Solid colored bars do not necessarily indicate that the probe fully covers the indicated genomic region. Therefore, caution is advised when interpreting results generated through off-label use. Probe map details based on UCSC Genome Browser GRCh37/hg19. Map components not to scale. Further information is available on request.

Need assistance or a quote?

Clinical Details

Receptor tyrosine kinases as well as Janus kinases (JAKs) have multiple functions in the signal transmission of cytokines and growth factors. Furthermore, constitutively enhanced JAK phosphorylation levels play critical roles in chronic inflammatory processes and cancer development. Chromosomal rearrangements involving JAK2, leading to constitutive activation of the kinase, have been detected in several patients with myeloproliferative neoplasm (MPN) or myelodysplastic syndrome (MDS). While ETV6-JAK2 and BCR-JAK2 fusion genes, resulting from translocations of the type t(9;12)(p24;p13) and t(9;22)(p24;q11), respectively, have been reported only in a small number of patients, pericentriolar material 1 (PCM1)-JAK2 represents the most frequent JAK2 fusion gene. The responsible translocation generating the described fusion is t(8;9)(p22;p24.1). Multiple breakpoints have been identified.
In 2017, the WHO updated the category 'myeloid/lymphoid neoplasms with eosinophilia and gene rearrangement' by adding a provisional entity, PCM1-JAK2. All mentioned neoplasms described in this category are associated with rearrangements or (rarely) mutations of four tyrosine kinases: PDGFRA, PDGFRB, FGFR1 or JAK2, respectively. As PCM1-JAK2 fusions are associated with a poor prognosis, only allogeneic hematopoietic stem cell transplantation is considered to be rather successful, although first small studies using the JAK2 inhibitor ruxolitinib as treatment for patients with PCM1-JAK2 positive chronic eosinophilic leukemia, not otherwise specified, have shown promising short term remission.

Clinical Applications

  • Chronic Myelogenous Leukemia and Myeloproliferative Neoplasms (CML/MPN)
Need assistance or a quote?

Images

XL t(8;9) PCM1/JAK2 DF

XL t(8;9) PCM1/JAK2 DF hybridized to bone marrow cells, one aberrant cell is shown. A translocation t(8;9) has occurred generating a signal pattern of two colocalization/fusion signals, one green and one orange signal.

Need assistance or a quote?

Expected Patterns

Expected Pattern 1

Normal Cell:
Two green (2G) and two orange (2O) signals.

Expected Pattern 2

Aberrant Cell (typical results):
One green (1G), one orange (1O), and two greenorange colocalization/fusion signals (2GO) resulting from a reciprocal translocation between the respective loci.

Need assistance or a quote?

Literature

  • Lierman et al (2012) Blood 120:1529-1531
  • Rumi et al (2013) J Clin Oncol 31:e269-e271
  • Reiter and Gotlib (2017) Blood 129:704-714

Downloads

News

MetaSystems DM2019 Largest in History

About 100 guests from 36 countries met on the XVIII. MetaSystems Distributor Meeting (DM) in November to exchange experiences and to get to know new trends and developments at MetaSystems.

MetaSystems DM2019 Largest in History

Second MetaSystems User Day in Altlussheim, Germany

Neon, the outstanding MetaSystems case and image management system, offers many tools and helpful gadgets to streamline routine workflows, for example in cytogenetics labs. The second MetaSystems User Day, addressed to MetaSystems clients from Germany, Austria, and Switzerland, provided in different workshops knowledge helping to unleash the full power of the system.

Second MetaSystems User Day in Altlussheim, Germany